{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:28:42Z","timestamp":1792898922250,"version":"4.5.0"},"reference-count":58,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Oritavancin (ORI) is a semisynthetic lipoglycopeptide approved as a single 1200 mg dose intravenous infusion for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive organisms in adults. The pharmacokinetic\/pharmacodynamic (PK\/PD) linear kinetic profile and long terminal half-life (~393 h) of ORI make it therapeutically attractive for the treatment of other Gram-positive infections for which prolonged therapy is needed. Multidose regimens are adopted in real-world clinical practice with promising results, but aggregated efficacy data are still lacking. A comprehensive search on PubMed\/Medline, Scopus, Cochrane and Google Scholar databases was performed to include papers published up to the end of January 2023. All articles on ORI multiple doses usage, including case reports, with quantitative data and relevant clinical information were included. Two reviewers independently assessed papers against the inclusion\/exclusion criteria and for methodological quality. Differences in opinion were adjudicated by a third party. From 1751 potentially relevant papers identified by this search, a total of 16 studies met the inclusion criteria and were processed further in the final data analysis. We extracted data concerning clinical response, bacteriologic response, mortality and adverse events (AEs). From the 16 included papers, 301 cases of treatment with multidose ORIs were identified. Multidose regimens comprised an initial ORI dose of 1200 mg followed by 1200 mg or 800 mg subsequent doses with a varying total number and frequency of reinfusions. The most often treated infections and isolates were osteomyelitis (148; 54.4%), ABSSSI (35; 12.9%) and cellulitis (14; 5.1%); and MRSA (121), MSSA (66), CoNS (17), E. faecalis (13) and E. faecium (12), respectively. Clinical cure and improvement by multidose ORI regimens were observed in 85% (231\/272) and 8% (22\/272) patients, respectively. Multidose ORI was safe and well tolerated; the most frequent AEs were infusion-related reactions and hypoglycemia. A multidose ORI regimen may be beneficial in treating other Gram-positive infections besides ABSSSIs, with a good safety profile. Further studies are warranted to ascertain the superiority of one multidose ORI scheme or posology over the other.<\/jats:p>","DOI":"10.3390\/antibiotics12101498","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T09:39:32Z","timestamp":1695980372000},"page":"1498","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The Clinical Efficacy of Multidose Oritavancin: A Systematic Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7809-077X","authenticated-orcid":false,"given":"Giammarco","family":"Baiardi","sequence":"first","affiliation":[{"name":"Pharmacology and Toxicology Unit, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy"},{"name":"Clinical Pharmacology Unit, Ente Ospedaliero Ospedali Galliera, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0973-6188","authenticated-orcid":false,"given":"Michela","family":"Cameran Caviglia","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Unit, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy"},{"name":"Clinical Pharmacology Unit, Ente Ospedaliero Ospedali Galliera, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Piras","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Unit, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy"},{"name":"Clinical Pharmacology Unit, Ente Ospedaliero Ospedali Galliera, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Sacco","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Unit, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy"},{"name":"Clinical Pharmacology Unit, Ente Ospedaliero Ospedali Galliera, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Prinapori","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ente Ospedaliero Ospedali Galliera, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Cristina","sequence":"additional","affiliation":[{"name":"Operating Unit Hospital Hygiene, Ente Ospedaliero Ospedali Galliera, 16128 Genoa, Italy"},{"name":"Department of Health Sciences, University of Genoa, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8460-0262","authenticated-orcid":false,"given":"Francesca","family":"Mattioli","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Unit, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy"},{"name":"Clinical Pharmacology Unit, Ente Ospedaliero Ospedali Galliera, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7127-2893","authenticated-orcid":false,"given":"Marina","family":"Sartini","sequence":"additional","affiliation":[{"name":"Operating Unit Hospital Hygiene, Ente Ospedaliero Ospedali Galliera, 16128 Genoa, Italy"},{"name":"Department of Health Sciences, University of Genoa, 16132 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1085-0442","authenticated-orcid":false,"given":"Emanuele","family":"Pontali","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Ente Ospedaliero Ospedali Galliera, 16128 Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"ref_1","unstructured":"U.S. Food and Drug Administration (2023, June 16). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=206334."},{"key":"ref_2","unstructured":"European Medicines Agency Science Medicines Health (2023, June 16). Tenkasi (Previously Orbactiv). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tenkasi-previously-orbactiv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/AAC.02663-14","article-title":"Structural Variations of the Cell Wall Precursor Lipid II and Their Influence on Binding and Activity of the Lipoglycopeptide Antibiotic Oritavancin","volume":"59","author":"Engels","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1021\/bi052660s","article-title":"Structures of Staphylococcus aureus Cell-Wall Complexes with Vancomycin, Eremomycin, and Chloroeremomycin Derivatives by 13C{19F} and 15N{19F} Rotational-Echo Double Resonance","volume":"45","author":"Kim","year":"2006","journal-title":"Biochemistry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jmb.2008.01.031","article-title":"Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus","volume":"377","author":"Kim","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_7","first-page":"23","article-title":"From Vancomycin to Oritavancin: The Discovery and Development of a Novel Lipoglycopeptide Antibiotic","volume":"9","author":"Allen","year":"2010","journal-title":"Anti-Infect. Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Infect. Agents)"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1128\/AAC.00603-08","article-title":"Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus","volume":"53","author":"Belley","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1128\/AAC.00760-10","article-title":"Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci to Effect Rapid Bacterial Killing","volume":"54","author":"Belley","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/jac\/dkp126","article-title":"Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium","volume":"63","author":"McKay","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (2020, January 01). Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 10.0, 2020 2020, 0\u201377. Available online: http:\/\/www.eucast.org\/clinical_breakpoints."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/cid\/civ311","article-title":"Oritavancin: A Long-Half-Life Lipoglycopeptide","volume":"61","author":"Saravolatz","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diagmicrobio.2004.06.007","article-title":"Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects","volume":"50","author":"Bhavnani","year":"2004","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1093\/cid\/cir921","article-title":"Macrophage Killing of Bacterial and Fungal Pathogens Is Not Inhibited by Intense Intracellular Accumulation of the Lipoglycopeptide Antibiotic Oritavancin","volume":"54","author":"Baquir","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1128\/AAC.47.5.1700-1706.2003","article-title":"Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection","volume":"47","author":"Boylan","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1093\/cid\/cis001","article-title":"In Vivo Activity of Oritavancin in Animal Infection Models and Rationale for a New Dosing Regimen in Humans","volume":"54","author":"Ambrose","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1128\/AAC.01428-12","article-title":"Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic\/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection","volume":"57","author":"Belley","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections","volume":"370","author":"Corey","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-Dose Oritavancin Versus 7\u201310 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study","volume":"60","author":"Corey","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e01919-17","DOI":"10.1128\/AAC.01919-17","article-title":"Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies","volume":"62","author":"Corey","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.00176-15","article-title":"Population Pharmacokinetic Analysis for a Single 1,200-Milligram Dose of Oritavancin Using Data from Two Pivotal Phase 3 Clinical Trials","volume":"59","author":"Rubino","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1128\/AAC.00231-09","article-title":"Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia","volume":"53","author":"Rubino","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lupia, T., De Benedetto, I., Bosio, R., Shbaklo, N., De Rosa, F.G., and Corcione, S. (2023). Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments. Life, 13.","DOI":"10.3390\/life13040959"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/phar.1957","article-title":"Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin","volume":"37","author":"Delaportas","year":"2017","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.2057","article-title":"Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections","volume":"38","author":"Schulz","year":"2017","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/IPC.0000000000000517","article-title":"Oritavancin for the Treatment of Daptomycin Nonsusceptible Vancomycin-Resistant Enterococci Osteomyelitis","volume":"26","author":"Foster","year":"2018","journal-title":"Infect. Dis. Clin. Pr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/IPC.0000000000000599","article-title":"Successful Treatment of Methicillin-Resistant Staphylococcus aureus Vertebral Osteomyelitis with Outpatient Oritavancin Therapy","volume":"26","author":"Ruggero","year":"2018","journal-title":"Infect. Dis. Clin. Pr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1871526517666161108130148","article-title":"Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem","volume":"17","author":"Antony","year":"2017","journal-title":"Infect. Disord.-Drug Targets"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00949","DOI":"10.1016\/j.idcr.2020.e00949","article-title":"Successful treatment of a prosthetic hip infection due to Enterococcus faecalis with sequential dosing of oritavancin and prosthesis preservation without prosthetic joint surgical manipulation","volume":"22","author":"Nguyen","year":"2020","journal-title":"IDCases"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-020-00452-z","article-title":"Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs","volume":"21","author":"Ahiskali","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijantimicag.2018.11.023","article-title":"Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review","volume":"53","author":"Chastain","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dahesh, S., Wong, B., Nizet, V., Sakoulas, G., Tran, T.T., and Aitken, S.L. (2019). Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02622-18"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ofz479","DOI":"10.1093\/ofid\/ofz479","article-title":"The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections","volume":"6","author":"Redell","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40801-020-00195-7","article-title":"Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study","volume":"7","author":"Chundi","year":"2020","journal-title":"Drugs - Real World Outcomes"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40801-020-00192-w","article-title":"Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience","volume":"7","author":"Brownell","year":"2020","journal-title":"Drugs - Real World Outcomes"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"ofv156","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_39","unstructured":"Terrero Salcedo, D.A., El-Herte, R., and Granada, M. (2018). Oritavancin for the Treatment of Infective Endocarditis Due to Gram-Positive Organism. Ann. Case Rep., ACRT-202."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New Lipoglycopeptides","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jgar.2021.04.013","article-title":"Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: A systematic review and meta-analysis","volume":"25","author":"Zhang","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-022-00529-z","article-title":"Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis","volume":"21","author":"Liu","year":"2022","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/QCO.0000000000000800","article-title":"New drugs for methicillin-resistant Staphylococcus aureus skin and soft tissue infections","volume":"35","author":"Hindy","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bloem, A., Bax, H.I., Yusuf, E., and Verkaik, N.J. (2021). New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081743"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1089\/mdr.2020.0171","article-title":"Therapeutic Options for Infections Due to vanB Genotype Vancomycin-Resistant Enterococci","volume":"27","author":"Riccardi","year":"2021","journal-title":"Microb. Drug Resist."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e0261420","DOI":"10.1128\/aac.02614-20","article-title":"New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides","volume":"66","author":"Tran","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2146\/ajhp110572","article-title":"Oritavancin: An investigational lipoglycopeptide antibiotic","volume":"70","author":"Karaoui","year":"2013","journal-title":"Am. J. Heal. Pharm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1185\/03007995.2015.1058248","article-title":"Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): A systematic review and network meta-analysis","volume":"31","author":"Thom","year":"2015","journal-title":"Curr. Med Res. Opin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-016-0145-7","article-title":"Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study","volume":"6","author":"Anastasio","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s40801-020-00196-6","article-title":"Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway","volume":"7","author":"Whittaker","year":"2020","journal-title":"Drugs-Real World Outcomes"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Redell, M., Moeck, G., Lucasti, C., Durso, S., Kennedy, C., Fusaro, K., Loutit, J., and Dudley, M. (2018). A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent with the Phase 3 SOLO Program. Open Forum Infect. Dis., 5.","DOI":"10.1093\/ofid\/ofy051"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s40801-020-00194-8","article-title":"Real-World Use of Oritavancin for the Treatment of Osteomyelitis","volume":"7","author":"Scoble","year":"2020","journal-title":"Drugs-Real World Outcomes"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"ofw274","DOI":"10.1093\/ofid\/ofw274","article-title":"Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results from the SOLO Clinical Trials","volume":"4","author":"Lodise","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1128\/AAC.00029-11","article-title":"The SIMPLIFI Study Team Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: An Analysis of the SIMPLIFI Trial","volume":"55","author":"Dunbar","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s40801-020-00188-6","article-title":"A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis","volume":"7","author":"Rose","year":"2020","journal-title":"Drugs-Real World Outcomes"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Belley, A., Robson, R., Francis, J.L., Adcock, D.M., Tiefenbacher, S., Rubino, C.M., Moeck, G., Sylvester, D., Dudley, M.N., and Loutit, J. (2017). Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01968-16"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"2016 5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/10\/1498\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:02:16Z","timestamp":1760130136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/10\/1498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["antibiotics12101498"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12101498","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}